Li-Yuan Bai

17PUBLICATIONS
147CO-AUTHORS
Tumour immunologyMolecular targetsPredictive and prognostic markersChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Sep 07, 2026
Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors.

|Jul 02, 2026
Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.

|Jun 25, 2026
Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Phase II, Open-Label, Randomized Study.

|Jun 01, 2026
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.

|Dec 10, 2025
Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancer.

Hsiu-Tzu Wang, Yung-Luen Yu, Wen-Jyi Lo

|Dec 01, 2025
Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma.

Keun-Wook Lee, Li-Yuan Bai, Minkyu Jung

Pageof 3

Frequent Collaborators

4 joint publications

Keun-Wook Lee

4 joint publications

Li-Tzong Chen

3 joint publications

Jen-Shi Chen

3 joint publications

Min-Hee Ryu